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Abstract
Introduction: Adults with Down syndrome (DS) are at exceptionally high risk for
Alzheimer’s disease (AD), with virtually all individuals developing key neuropatholog-
ical features by age 40. Identifying biomarkers of AD progression in DS can provide
valuable insights into pathogenesis and suggest targets for disease modifying treat-
ments.
Methods: We describe the development of a multi-center, longitudinal study of
biomarkers of AD inDS. The protocol includes longitudinal examination of clinical, cog-
nitive, blood and cerebrospinal fluid-based biomarkers, magnetic resonance imaging
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andpositron emission tomographymeasures (at 16-month intervals), aswell as genetic
modifiers of AD risk and progression.
Results: Approximately 400 individuals will be enrolled in the study (more than 370
to date). Themethodological approach from the administrative, clinical, neuroimaging,
omics, neuropathology, and statistical cores is provided.
Discussion: This represents the largest U.S.-based, multi-site, biomarker initiative of
AD inDS. Findings can informothermultidisciplinary networks studyingAD in the gen-
eral population.
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1 INTRODUCTION
Adults with Down syndrome (DS) are at exceptionally high risk for
Alzheimer’s disease (AD), with virtually all individuals developing
neuropathology by 40 years of age, consistent with a brain tissue
AD diagnosis, including amyloid plaques, neurofibrillary tangles, and
granulovacuolar degeneration.1-4 The prevalence of dementia in
DS increases with age, with the majority of individuals exhibiting
indications of clinical decline by 60 years of age.5,6
Within the general adult population, there is a need to understand
critical pathophysiological mechanisms of AD to provide a window for
therapeutic intervention.7 Individuals with DS share the same need.
However, understanding the conversion to dementia inDS is often con-
founded by other factors, including varying degrees of baseline intel-
lectual disability8 and associated medical comorbidities.9 In addition,
there is considerable variability in the age of onset of dementia in
DS, ranging from prior to age 40 to over age 70.10 Empirically sup-
ported methods for detecting AD-related clinical progression in DS,
the biological characterization of the preclinical and early phases of
this progression, and the identification of risk factors are critical for
the development of effective interventions.11 This report will focus on
the methods used to address these areas in a multidisciplinary, longi-
tudinal study of biomarkers of AD in adults with DS, examining clinical,
cognitive, blood and cerebrospinal fluid (CSF)-based fluid biomarkers,
magnetic resonance imaging (MRI) and positron emission tomography
(PET) measures, as well as genetic polymorphisms associated with AD
progression.
2 RATIONALE FOR THE APPROACH
The etiology of AD inDS (trisomy 21) is linked to a lifelong overproduc-
tion of amyloid beta (Aβ). This overproduction is due to the presence
of three copies of chromosome 21, each containing one copy of the
amyloid precursor protein (APP) gene (ultimately leading to a 1.5-fold
increase in the production of Aβ protein).12-14 The rare instance of a
partial trisomy 21, in which there is duplication but not triplication of
APP, is associated with the absence of clinical and pathological signs
of AD, demonstrating the key role played by APP overexpression.14,15
The early striatal pattern of Aβ deposition in DS is similar to that
in autosomal dominant AD (ADAD) mutation carriers.16,17 Yet, it is
clear that factors in addition to overexpression of APP contribute to
the wide variation in age of onset of AD in the DS population.3,18,19
Gaining a full understanding of these modifiers of risk could provide
important insights into pathways representing promising targets for
disease-modifying treatments.
AD in DS provides an example of both amplified vulnerability and
an opportunity to examine protective factors thatmaymodify the rela-
tions among Aβ, neurodegeneration, and dementia. Thus, a range of
genotypic and phenotypic variations in adults with DS may serve to
increase relative risk (eg, hypercholesterolemia, neuroinflammation) or
act asprotective factors (eg, highestrogenbioavailability, lowerperiph-
eral vascular disease, higher baseline IQ).20,21 A large-scale biomarker
initiative, similar to the Alzheimer’s Disease Neuroimaging Initiative
(ADNI) or the Dominantly Inherited Alzheimer Network (DIAN), tar-
geting AD in DS is needed to identify these factors, to provide the field
with empirically validated tests that can inform diagnosis and predict
risk, and to support the development of therapeutic trials specifically
designed for the prevention and treatment of AD in this population.
ADNI was designed to develop clinical, imaging, genetic, and biochem-
ical biomarkers for the early detection and tracking of AD in the gen-
eral population through a public-private partnership, with a hallmark
feature of providing data without embargo to scientists around world.
The DIAN study focuses on both observational studies and clinical tri-
als, using clinical, imaging, genetic, and biochemical biomarkers simi-
lar to ADNI, to identify solutions to treat or prevent autosomal domi-
nant AD. In recognition of the importance of these issues facing adults
with DS, the U.S. National Institute on Aging (NIA) and the Eunice
Kennedy Shriver National Institute on Child Health and HumanDevel-
opment (NICHD) provided the resources to support a similar large-
scale biomarker initiative focusing on DS, establishing the program
described herein.
Our current knowledge indicates that the earliest signs of ADdevel-
opment in the general population occur at least 20 years prior to
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the appearance of clinical symptoms.22 This hypothesized “cascade”
starts with the aggregation of soluble Aβ42 in the brain into insol-
uble plaques, as evidenced by early reductions in concentrations of
Aβ42 in the cerebrospinal fluid (CSF), followed by amyloid deposition
detectable by positron emission tomography (PET). Increases in CSF
tau andphosphorylated tau, indicative of neuronal injury, andneurofib-
rillary tangle formation, respectively, ensue, followed by subsequent
changes in brain structure (eg, decreased hippocampal volume), and
glucose hypometabolism.23 Finally, early clinical symptoms begin to be
detected, most commonly in episodic memory.24,25 While it is hypoth-
esized that the pathophysiological features of AD in adults with DS
are similar to that of late-onset AD (LOAD), the course of the AD dis-
ease process is only partially understood. The mean age of diagnosis
of AD in DS is 55.8 years and survival after a diagnosis of dementia
appears to be shorter in comparison to LOAD.26 Unlike the general
population, there is ample evidence of deposition of insoluble amyloid
in the brains of the vastmajority of adultswithDS by the early 40s (and
soluble amyloid much earlier),27,28 along with documented changes in
brain structure (eg, enlarged lateral ventricles, reduced hippocampal
volume).28-30
Comparison of the risk, biomarker, and genetic profiles in DS with
those with AD in the general population (as well as with other groups,
such as individuals with ADAD) can help to define common pathways
and mechanisms. It is an ultimate goal of all of these investigations to
identify a window for therapeutic intervention before the inexorable
decline associated with AD.
3 PROTOCOL OVERVIEW
The Alzheimer’s Biomarker Consortium-Down Syndrome (ABC-DS)
was formed in 2015, combining two programs developed indepen-
dently in response to an initiative of the U.S. National Institutes of
Health (NIH-RO1-RFA-AG-15-011). Harmonization of these two sep-
arately funded programs was intended to produce standardization of
diverse andcomplexprocedures. This effortwas largely successfulwith
some exceptions, as described in the Challenges section below. This
unification process helped to address many of the general obstacles
in conducting longitudinal research focused on DS, including methods
for surrogate consent, appropriate recruitment materials, participant
retention, data security, and safety oversight.
While the ABC-DS developed into a unified study, the original
program designations prior to harmonizationwere preserved in recog-
nition of components unique to these two separate but closely collabo-
rating programs. The first, titled Alzheimer’s Disease Down Syndrome
(ADDS), includes enrolling sites in New York, NY (Columbia Univer-
sity/NewYork State Institute forBasic Research inDevelopmentalDis-
abilities); Boston, MA (Massachusetts General Hospital, Harvard Uni-
versity); and Irvine, CA (the University of California, Irvine) supported
by collaborators at the Johns Hopkins University Schools of Medicine
and Public Health and the University of North Texas Health Science
Center. The second program, titled Neurodegeneration in Aging Down
Syndrome (NiAD), includes an additional four enrolling sites located
RESEARCH INCONTEXT
1. Systematic review: We describe the development of
a multi-center, longitudinal study of biomarkers of
Alzheimer’s disease (AD) in Down syndrome (DS) involv-
ing seven performance sites. The protocol includes exam-
ination of clinical, cognitive, blood and cerebrospinal
fluid-based biomarkers, magnetic resonance imaging
(MRI) and positron emission tomography (PET) measures
(at 16-month intervals), and genetic modifiers of AD risk
and progression.
2. Interpretation: More than 400 individuals are being
enrolled. This represents the largest U.S.-based, multi-
site, biomarker initiative to target AD in the DS pop-
ulation. It has similarities to other efforts such as the
Alzheimer Disease Neuroimaging Initiative (ADNI) and
the Dominantly Inherited Alzheimer Network (DIAN).
3. Future directions: The Alzheimer’s Biomarker
Consortium-Down Syndrome (ABC-DS) is poised to
have a substantial impact on our ability to characterize
AD in DS, both by identifying those biomarkers that
clarify risk for transition from cognitive stability to early
clinical progression to AD and in the identification of
biomarkers of preclinical AD progression.
in Pittsburgh, PA (University of Pittsburgh); Madison, WI (University
of Wisconsin); St. Louis, MO (Washington University); and Cambridge,
England (University of Cambridge). Each enrolling site has been con-
ducting ongoing recruitment with a participation target of between 50
and 100 adults with DS ages 25 years and older (for NiAD) and 40 or
older (for ADDS). The ABC-DS protocol comprises research visits at
baseline, 16months, and 32months. These time intervals were chosen
based upon the extensive knowledge of the research team members
regarding the time course of AD progression, as well as considerations
related to safety and participation burden for a population with intel-
lectual disability. A3-monthappointmentwindowaround these follow-
up intervals is allowed to provide sufficient flexibility for scheduling,
due to participants’ and informants’ other demands on their time.
The protocol components are listed in Table 1. Study visits have typ-
ically occurred across 2 separate days. The cognitive assessment bat-
tery, physical/ neurological exam, and caregiver questionnaires tend to
be scheduled on the first day. TheMRI and PET scans, blood draws and
optional lumbar puncture (LP) for the collection of CSF are typically
scheduled on the second day (the actual order of assessments may dif-
fer slightly across sites). Sometimes a third day is needed to complete
the assessments. Table 1 lists the time points and procedures of the
study. (Note that some procedures that do not require on-site facilities
may be conducted during staff visits to participants’ homes or program
sites when logistically necessary.)
A few important differences in the ADDS and NiAD protocols were
deliberately retained after harmonization. ADDS enrollment focuses
4 of 15 HANDEN ET AL.
TABLE 1 Alzheimer’s Biomarkers Consortium–Down Syndrome
assessments
Procedure Month 0 Month 16 Month 32
Cognitive battery X X X
Physical/neurological exam X X X
Informant interviews/questionnaires X X X
Blood draw X X X
MRI X X
a
X
Amyloid PET X X
a
X
Tau PET X
b
X
b
X
b
FDG PET X
c
Optional LP/CSF X
d
X
d
X
d
Consensus classification X X X
aMonth 16 magnetic resonance imaging (MRI) and amyloid PET for ADDS
group only.
bNiAD conducts Tau PET month 0 and 32; ADDS conducts Tau PET month
16 and 32.
cNiAD only.
dADDS collects CSF at month 0, 16, and 32; NiAD collects cerebrospinal
fluid (CSF) at month 16.
Abbreviations: ADDS, Alzheimer’s Disease Down Syndrome; CSF, cere-
brospinal fluid; FDG, fluorodeoxyglucose; LP, lumbar puncture; MRI, mag-
netic resonance imaging; NiAD, Neurodegeneration in Aging Down Syn-
drome; PET, positron emission tomography.
on individuals 40 years of age and older with the aim of identifying
transitions from cognitive stability to early clinical progression of AD
and from mild cognitive impairment (MCI-DS) to frank dementia. A
major goal is to determine those biomarkers that clarify risk for these
transitions and that can inform differential diagnosis. NiAD shares
these broad goals, but permits enrollment of adults as young as 25
to discover biomarkers of preclinical AD progression (ie, prior to the
MCI-DS stage), understanding that these earliest stages of disease can
occur decades prior to symptom onset.
Asdescribed inTable1, therewerealsodifferencesbetween the two
protocols for when PET scans and LPs are conducted. In addition, only
the NiAD group has conducted FDG PET scans (at the month 16 visit).
Finally, the NiAD protocol has included enrollment of a biomarker ref-
erence group composed of a smaller number of age-matched siblings
withoutDS. Siblings have tobe freeof symptomsof dementia (assessed
via the Montreal Cognitive Assessment [MOCA]31 and the Eight-Item
Interview to Differentiate Aging and Dementia [AD8]32,33) or other
neurological disorders. They undergo the same scanning, and LP and
blood draws, but are not administered additional cognitive testing,
physical/neurological examinations, or informant interviews.
4 INSTITUTIONAL REVIEW BOARDS AND
CONSENT
Institutional Review Board (IRB) approval and informed consent
(and assent when appropriate) have been obtained from all study
participants or their proxy/legally authorized representative (LAR). DS
is more common than all other forms of autosomal dominant dementia
combined. However, the field has not yet answered a number of
ethical imperatives for determining the ability of individuals withDS to
participate in longitudinal studies such as ABC-DS as well as in clinical
trials.34 Regulations for surrogate consent in biomedical research
differ across states. For example, some states require that a LAR sign
the consent for an adult with a developmental disability to participate
in research (while the adult with DS signs an assent). Other states
assume that all adults with developmental disabilities are capable
of consenting for themselves unless proven otherwise. In addition,
permission for procedures considered “more thanminimal risk” (eg, LP,
PET) is restricted for residents of some states because of regulations
originally developed to protect people with developmental disorders
from exploitation. Such restrictions tend to be in response to a history
of controversial research in individuals with intellectual disability,35
leading to the adoption of rigorous protections for research participa-
tion. While every ABC-DS performance site has obtained regulatory
approval to conduct the entire project protocol, a small minority of
prospective study enrollees are restricted to participating in only
those procedures deemed to be minimal risk. The ethics of clinical
research for individuals with intellectual disability remains a complex
issue36,37 and ABC-DS is contributing to that discussion.
5 PARTICIPANT RECRUITMENT
Participants have been recruited both locally and regionally. Some sites
have outpatient clinics that specifically serve adults with DS that pro-
vide an excellent referral source. All participating sites have legacy
studies involving adults with DS, many of whose participants have
enrolled in the ABC-DS effort. Sites have also included study infor-
mation on websites and in newsletters published by local DS advo-
cacy groups and have also used university-supported efforts to enroll
participants in research. Finally, ABC-DS investigators and staff have
focused on community engagement, including developing educational
videos and presenting at local, regional, and national conferences. Of
particular importance has been the availability of a link describing this
researcheffort throughDSConnect,38 which is a research registry sup-
ported by NICHD.
6 ADMINISTRATIVE CORE
NiAD and ADDS have separate administrative sites located at the Uni-
versity of Pittsburgh and Columbia University, respectively. Together,
the administrative units manage all components of ABC-DS including
budget, frequent teleconferences, and monthly communication with
NIA/NICHD officials. In addition, an annual in-person investigators
meeting is held. The Consortium’s Data Safety Monitoring Board,
comprising members unaffiliated with the ABC-DS, meets every 6
months to review progress and to address any risk-related concerns
associated with participation. This independent oversight ensures that
the program is continuing to be conducted consistent with the highest
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ethical standards. Website communications are maintained for fam-
ilies with links to participating institutions as well as to NIA/NICHD.
Participant blood samples are shipped, processed, and stored at the
National Centralized Repository for Alzheimer’s Disease and Related
Dementias (NCRAD). NCRAD subsequently provides blood samples
to ABC-DS investigators to conduct protocol-related genetics, pro-
teomics, and metabolomics analyses. In addition, outside investigators
can request access to samples for additional studies of their own. An
ABC-DS biospecimens committee has been established to review such
requests to ensure that these valuable samples are utilized effectively
(eg, to avoid redundancy with studies already in progress). Once
approved, NCRADmakes samples available to these qualified, outside
researchers. CSF samples are shipped to the Fagan Biomarker Lab at
Washington University for processing and analyses. This lab similarly
stores CSF samples to be made available to outside investigators. All
ABC-DS data, including unprocessed MRI and PET scans, are stored
and made available to external researchers through the Laboratory of
Neuro Imaging (LONI) data repository at the University of Southern
California (USC).39 A Publication Committee coordinates dissemina-
tion of findings generated by ABC-DS investigators and minimizes
duplication of effort within the ABC-DS team. This committee also
facilitates access to ABC-DS data when requested by outside qualified
investigators.
Finally, cross-site training has been an important part of the har-
monization process. Subcommittees were formed to harmonize the
neuropsychological assessments, clinical evaluations, neuroimaging
sequences, and blood and CSF processing. As a result, ABC-DS has
created discipline-specific protocols, case report forms, and data dic-
tionaries. The harmonization process was facilitated further through
several NIA supplements to expand biomarker availability, investigate
sleep parameters, and to add additional ligands to the PET procedures.
7 CLINICAL AND NEUROPSYCHOLOGICAL
EVALUATIONS
The potential impact of medical and psychiatric comorbidities on
cognitive performance profiles of adults with DS has been well
documented.8 Some of these comorbidities can be signs of AD clinical
progression or can indicate the presence of some unrelated condi-
tion with a clinical presentation that can mimic AD (or a different
aging-related dementing disorder). To address these potential compli-
cations, a standardized medical history, chart review, and neurological
examination are conducted to provide key information needed for
differential diagnosis as well as clinical dementia status. Conditions
of particular interest in this population include thyroid dysfunction,
sleep apnea, seizures, neuropsychiatric conditions, medication use,
and other systemic illnesses.
The ABC-DS group has selected a set of neuropsychological mea-
sures that have the strongest evidence base for defining different
stages of dementia. Most of these tools were developed specifically
for adults with DS, as the available tools used to assess aging-related
dementia in “neurotypical” adults would show performance profiles
well below criteria for a diagnosis of frank dementia, due to develop-
mental impairments unrelated to AD. In DS samples, declines in cogni-
tion are associatedwith earlyAD-related neuropathological changes27
as well as with the onset of MCI-DS and dementia.40 These include
declines in measures of episodic memory, attention, executive func-
tioning, visuospatial ability, and motor planning and coordination.41-45
For the ABC-DS effort, the choice of specific procedures was based
upon extensive past experience and the published literature indicat-
ing that: (1) almost all adults with DS can understand instructions and
the task demands, (2) most individuals can perform significantly above
floor (>2 standard error of the mean [SEMs]) prior to developing AD-
related decline, (3) measures have good psychometric properties, and
(4) measures are sensitive to early indications of AD clinical progres-
sion and subsequent decline.Manyof the selectedmeasureswere used
in our own related legacy studies of dementia in DS, and these data
have proven to be a rich resource for participant recruitment and for
tracking status over time. Informant and direct-testingmeasures in the
ABC-DS protocol are listed in Table 2, along with the primary cogni-
tive/functional domains the tests are intended to assess. It should be
noted that in addition to theharmonized coreofmeasures usedbyboth
the ADDS and NiAD sites, a number of supplemental assessment tools
were included at various sites to evaluate their utility/validity.
7.1 Diagnostic determination
Clinical dementia status has beendetermined individually for each par-
ticipant following eachassessment cycle during aConsensusCaseCon-
ference. These discussions include at least three study staff who have
clinical training (eg, licensed clinical psychologist or physician) or long-
standing expertise in evaluatingdementia in theDSpopulation. The fol-
lowing information is considered: (1) review of themedical and psychi-
atric history as well as findings from the neurological exam, (2) “core”
informant interviews, and (3) the participant’s overall profile of perfor-
manceona “core”batteryofdirect tests. Forparticipantswhohavepar-
ticipated in the study atmultiple time points, all time points of informa-
tion are considered. Overall pattern of change in performance is con-
sidered rather than focusing on specific cutoff scores or any one mea-
sure. Performance is considered in relation to theparticipants’ baseline
IQ, medical and psychiatric conditions, and any major life events. Dur-
ing consensus determinations, study staff has been blind to the status
of all other ABC-DS biomarker findings, including apolipoprotein
E (APOE) genotype, MRI and PET findings, fluid biomarkers, and
supplemental measures of cognitive or functional status.
We classify participants into four groups, generally following the
recommendations of the AAMR-IASSIDWorking Group for the Estab-
lishment of Criteria for the Diagnosis of Dementia in Individuals with
DevelopmentalDisability.76,77 Participants have been classified as cog-
nitively stable (CS) if they are without cognitive or functional decline
beyond what would be expected with adult aging, per se. Mild cogni-
tive impairment (MCI-DS) is assigned for participants who have shown
some cognitive and/or functional decline that is greater than would
be expected with “healthy aging” but not of sufficient magnitude to
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TABLE 2 Harmonized core and supplemental measures
Domain Task ADDS NiAD
Mental status Down SyndromeMental Status Examination46 X X
Dementia Questionnaire for People with Learning Disabilities (DLD)47 X X
NTG-Early Detection Screen for Dementia (NTG-EDSD)48 X X
ModifiedMini-Mental Status Examination49 X
Test for Severe Impairment50 X
Severe Impairment Battery (SIB)51 X
Rapid Assessment for Developmental Disabilities (RADD)52 X
Functional abilities Vineland Adaptive Behavior Scale53 X X
AAMRAdaptive Behavior Scale54 X
Language/cognitive Categorical/Verbal Fluency55,56 X X
BostonNaming Test57 X
Expressive-OneWord Picture Vocabulary Test58 X
Peabody Picture Vocabulary Test59 X
Stanford-Binet (5th ed.) Abbreviated Battery60 X
Visuospatial construction Block Design and Extended Block Design46,61 X X
Beery Buktenica Developmental Test of VisualMotor Integration (VMI)62 X X
Memory Cued Recall Task63 X X
Rivermead BehavioralMemory Test for Children—Face & Picture Recognition64 X X
Selective Reminding Test65
Selective Reminding Test Post 10minute delay
XX
WISC-IVDigit Span Forward61 X
Forward Corsi Span62 X
WMS-IV LogicalMemory I & II66 X
Neuropsychiatric symptoms/
behavior problems
Neuropsychiatric Inventory (NPI)67 X X
Reiss Screen forMaladaptive Behavior68 X X
The Columbia University Scale for Psychopathology in Alzheimer’s Disease (CUSPAD)69 X
Psychiatric status and history X
Executive processing and speed StroopDog and Cat70 X X
The Purdue Pegboard71 X X
Dimensional Change Card Sort72 X
Flanker Inhibitory Control and Attention Task72 X
NEPSY Visual Attention Subtest73 X
Pattern Comparison Processing Speed72 X
Cancellation Task74 X
WISC-IVDigit Span Backward61 X
Backward Corsi Span62 X
Gait Tinetti Assessment Tool: Gait75 X X
Health status and life events Demographic Health Questionnaire X X
Comprehensive chart review X
Life stressors index [Seltzer, G, Personal Communication, 2002] X
Note: Harmonized Core is indicated in bold.
Abbreviations: ADDS, Alzheimer’s Disease Down Syndrome; NiAD, Neurodegeneration in Aging Down Syndrome.
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TABLE 3 Alzheimer’s Biomarker Consortium–Down Syndrome
(ABC-DS) cohort characteristics as of September 2019 (N= 370
participants)
Characteristics n (%)
Sex
Males 199 (54%)
Females 171 (46%)
Age
25 to 34 53 (14%)
35 to 44 110 (30%)
45 to 54 131 (35%)
55 to 64 69 (19%)
65+ 7 (2%)
Race
White 354 (96%)
Nonwhite 16 (4%)
Status
a
Cognitively stable 241 (68%)
MCI-DS 52 (15%)
Dementia 42 (12%)
Undetermined 18 (5%)
Co-occurring
Stroke 7 (2%)
Diabetes 19 (5%)
Hyperlipidemia 113 (31%)
Hypothyroidism 221 (60%)
Seizures 34 (9%)
Obesity 179 (48%)
APOE
Any ε4 allele 64 (17%)
Abbreviation:MCI-DS, mild cognitive impairment.
a353with consensus diagnosis.
meet dementia criteria. Participants have been classified as demented
if there is a history of progressive memory loss, disorientation, and
functional decline over a period of at least 1 year, and if no other med-
ical or psychiatric conditions that might result in or mimic dementia
are present (eg, traumatic life event, recent surgery). The ADDS sites
includeanadditional category, “possibledementia,”whichhasbeencol-
lapsed with the “dementia” category for purposes of analysis. Fidelity
has been ensured by close supervision of training and conducting an
independent second consensus diagnosis on a random subset of partic-
ipants at each site.
As the ABC-DS continues to actively recruit study participants, we
are only able to provide information on those enrolled in the cohort
to date. Table 3 summarizes the demographic characteristics of the
first 370 participants with DS as of September 2019. More than two
thirds of participants have been determined (via consensus confer-
ence) to be cognitively stable. Seventeen percent have at least one
APOE ε4 allele. The most commonly occurring medical comorbidities
are hypothyroidism, obesity, and hyperlipidemia.Over the past 3 years,
21 study participants have died (≈5% of the cohort). Finally, 96% of
the cohort is white, demonstrating the challenges of recruiting and
enrolling participants from under-representedminorities.
8 NEUROIMAGING STUDIES
The MRI- and PET-derived outcome measures have been harmonized
as much as possible between the seven clinical sites in the study. The
MRI acquisition plan (whose sequences are shown in Table 4) has fol-
lowed the guidance of the ADNI 3 and Human Connectome Project
(HCP) protocols. All MRI scans are read by a neuro-radiologist fol-
lowing institution-specific guidelines and any clinically significant find-
ings are reported to the participant’s primary care provider, desig-
nated representative, and/or family. The scans are analyzed for key
outcome measures by laboratories within the ABC-DS network with
expertise in the respective modality, following internal quality control
(QC) and analytic procedures. They are additionally uploaded to the
image repository and placed in quarantine pending the approval of
the QC procedures. The T1-weighted scans are used as the reference
images to indicate the quality of all of the imaging sequences. If theQC
inspection is deemed acceptable, then all of the imaging sequences for
each study participant are removed fromquarantine andmade accessi-
ble for image processing to outside researchers. Acceptable tolerance
of image quality is determined by researchers for each individual image
sequence (eg, motion tolerance in resting state functional MRI [rs-
fMRI]) to determine their inclusion for analyses and hypothesis testing.
PET scans have been acquired from the majority of participants
to quantitate the Aβ and tau burden (along with a subset of partici-
pants to measure glucose metabolism) for cross-sectional and longitu-
dinal analyses. The acquisition of the PET data closely adheres to the
ADNI specifications for uptake period and scanning duration for theAβ
([C-11]PiB—four sites and florbetapir/[F-18]AV-45—three sites), tau
(flortaucipir/[F-18]AV1451—all sites), and glucose metabolism (FDG—
three sites). The details for acquisition are listed in Table 5.
The initial harmonization process for the PET procedures across all
sites required consideration of initial protocol variations in the order
of scans at participant visits, the use of different PET radiotracers for
measuring Aβ deposition, and local regulatory requirements for radi-
ation use and exposure. The NiAD sites have been acquiring Aβ (PiB)
and tau scans at the baseline and 32-month visits. TheADDS sites have
been acquiringAβ (florbetapir) at the baseline and32-month visits, and
tau scans at the 16-month visit. Three of the four NiAD sites have been
acquiring FDG scans at the16-month visit. For harmonization across
sites, reconstruction parameters of the PET images have followed the
specifications defined by the ADNI trials for specific PET and PET/CT
scanner models. The Centiloid Scale was developed to permit compar-
isons between different Aβ radiotracers (eg, Pittsburgh compound B
[PiB] and florbetapir) in cross-sectional and longitudinal studies.78,79
It has not been previously studied in a cohort of adults with DS and
is a focus for our Neuroimaging Unit. The same tau (flortaucipir) and
8 of 15 HANDEN ET AL.
TABLE 4 Magnetic resonance imaging (MRI) studies
MRI scan sequence Purpose Outcomemeasures
T1-weightedMPRAGE Structural morphometry Cortical thickness, regional volumetry
T2-weighted Pathology detection/morphology Intracranial volume
T2-FLAIR Detection of ischemic disease Whitematter hyperintensities—volume
T2 Star Detection of hemorrhagic lesions Presence/location of cerebral microbleeds
DTI Integrity of whitematter tissue Fractional anisotropy
pASL
a
Index of cerebral perfusion Cerebral blood flow
Rs-fMRI Functional connectivity Network connectivity
aThe ASL sequence has been acquired only at four NiAD sites.
Abbreviations: DTI, diffusion tensor imaging; FLAIR, x; NiAD, Neurodegeneration in Aging Down Syndrome; pASL, pulsed arterial spin labeling; Rs-fMRI,
resting state functional magnetic resonance imaging.
TABLE 5 Positron emission tomography (PET) procedures
PET procedure
Targeted injected dose
(10% tolerance)
Uptake
period
PET acquisition
period
[C-11]PIB 15mCi
a
(555MBq) 0 to 40min 50 to 70min
Florbetapir ([F-18]AV45) 10mCią
a
(370MBq) 0 to 40min 50 to 70min
Flortaucipir ([F-18]AV1451) 10mCią
a
(370MBq) 0 to 65min 75 to 105min
[F-18]FDG 5mCi
a
(185MBq) 0 to 20min 30 to 60min
aMaximum injected dose is specific to each participating site as required by local restrictions.
glucose metabolism (fluorodeoxyglucose [FDG]) radiotracers have
been used across sites to enable harmonization of these measures.
Table 1 provides the time points for the administration of the MRI and
PET scans and any differences across sites.
9 OMICS STUDIES
The ABC-DS omic approaches have been designed to identify and
quantitate potential biomarkers of AD progression and risk modi-
fiers associated with genes (genomics), proteins (proteomics), and low
molecular weight molecules (metabolomics) obtained from blood and
CSF. The omics data are being used for two parallel lines of analy-
ses. First, we are testing specific hypotheses using targeted analyses,
whereinmarkers that havealreadybeen identified inprevious research
are being examined to validate those earlier findings, further distin-
guishing true associations from false discoveries. In addition, novel
biomarkers may emerge in the future and warrant rapid evaluation in
the ABC-DS cohort. Thus, in a parallel line of work, we are also employ-
ing untargeted approaches, wherein a far broader range of biomark-
ers is captured for discovery analysis. This combination of targeted and
untargeted omics approaches allows us to investigate specific a pri-
ori identified targets in addition to providing broad, unbiased omics
datasets to explore new hypotheses.
1. Targeted Approaches: Planned targeted omics studies have been
driven by current knowledge in the field aswell as previous findings
from members of our investigative team. We are targeting genes,
proteins, and metabolites involved in relevant biological pathways
including inflammation, oxidative stress, mitochondrial activation,
and lipid and cellular energymetabolism.80-83
a. Targeted Genomics Analysis: While collecting genome-wide asso-
ciation data (GWAS) using Illumina InfiniumGlobal ScreenArray
version 2.0, a priori determined canonical pathways of inflam-
mation, oxidative stress response, lipid and energy metabolism
are being examined to identify candidate genes or regions
related toAD risk and progression.We are using candidate gene
analysis to evaluate single nucleotide polymorphisms (SNPs)
and copy number variations (CNVs) to assess genetic contribu-
tion from genes likely (or known) to be involved in AD risk in
adults with DS, those with ADAD, as well as in the general pop-
ulation. In this rapidly evolving field, the candidate genes we are
investigating include APP, APOE, SOD1, S100β, SORL1, as well as
other genes that have been shown to be significantly associated
with AD risk.84
b. Targeted Proteomic Assays: Given recent literature on the poten-
tial utility of novel ultra-sensitive measures of plasma neurofil-
ament light chain (NfL), amyloid, and tau, the ABC-DS team is
using anautomatedultra-sensitive singlemolecule array (Simoa)
technology (Quanterix Corp.) to measure plasma amyloid (Aβ40,
Aβ42), total tau and NfL. Additional targeted ultra-sensitive
assayswill be added for future analyses. In addition to the Simoa
assays, we are quantifying a 21-protein panel as described in
the AD Blood Screen previously published by some of our team
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TABLE 6 Targeted proteomic andmetabolomic species
Targeted proteomics Targetedmetabolomics
ECL platform Simoa platform Lipidyzer Polarmetabolites
A2M Aβ1-40 Triacylglycerols (TAG) (502 lipids) Amino acid synthesis, metabolism and degradation
(50metabolites)
B2M Aβ1-42 Diacylglycerols (DAG) (67 lipids) Purinemetabolism (25metabolites)
CRP T-tau Free fatty acids (FFA) (28 lipids) Pyrimidine biosynthesis (20metabolites)
Eotaxin-3 NfL Cholesterol esters (CE) (34 lipids) Single carbonmetabolism and folatemetabolism
(17metabolites)
FABP3 Phosphatidylcholines (PC) (161
lipids)
Glycolysis, Gluconeogenesis and Pyruvatemetabolism
(12metabolites)
Factor 7 Phosphatidylethanolamines (PE) (233
lipids)
Citric acid cycle (11metabolites)
I-309 Lysophosphatidylcholines (LPC) (28
lipids)
Urea cycle (10metabolites)
IL-10 Lysophosphatidylethanolamines (PE)
(28 lipids)
Oxidative phosphorylation (7metabolites)
IL-18 Sphingomyelins (16 lipids) Sugar and amino sugar metabolism (7metabolites)
IL-5 Ceramides (56 lipids) Fatty acidmetabolism (6metabolites)
IL-6 Tryptophanmetabolism (6metabolites)
IL-7 Pentose phosphate pathway (5metabolites)
PPY Phenylalaninemetabolism (5metabolites)
SAA Vitaminmetabolism and biosynthesis (4 metabolites)
sICAM-1 Lipoic acid metabolism (2metabolites)
sVCAM-1 Nicotinate and nicotinamidemetabolism
(2metabolites)
TARC Others (81metabolites)
Tenacin-C
TNF-α
TPO
Note: The 24-metabolite panel is derived from 24 lipids andmetabolites collected in the Lipidyzer and PolarMetabolite panels.
Abbreviations: Aβ, amyloid beta; A2M, alpha 2 macroglobulin; B2M, beta 2 microglobulin; CRP, c-reactive protein; ECL, electrochemiluminescence; FABP3,
fatty acid binding protein; Factor 7, eotaxin3; factor VII; IL, I309; interleukin; NfL, neurofilament light chain; PPY, pancreatic polypeptide; SAA, serum amy-
loid A; sICAM-1, soluble intercellular adhesion molecule-1; sVCAM1, circulating vascular cell adhesion molecule-1; TARC, thymus and activation regulated
chemokine; TNF-α , tumor necrosis factor-alpha; TPO, thrombopoietin; T-tau, total tau.
members85 using an automated (HamiltonRobotics) systemand
the multi-plex MSD platform (Meso Scale Diagnostics, LLC; see
Table 6).
c. Targeted Metabolomics Assays: We are using stable Isotope dilu-
tion, multiple reaction monitoring, mass spectrometry (SID-
MRM-MS) for targeted quantitation of low molecular weight
metabolites involved in lipid and cellular energy metabolism.
Specifically, we are using the Lipidyzer platform (SCIEX, Ltd) to
quantitate ≈1100 lipids and a bespoke 270 metabolite panel
covering cellular energy and related metabolic pathways. These
methods allow for the extractionof our published24-metabolite
panel86 (see Table 6).
d. Targeted CSF Assays: In CSF we are employing the state-
of-the-art automated LUMIPULSE platform for immunoas-
say measurement of Aβ40, Aβ42, total tau, and phosphory-
lated tau181. We are using a microparticle-based immunoas-
say with Single Molecule Counting (SMC)™ utilizing anti-
bodies developed in the laboratory of Dr. Jack Ladenson at
Washington University to measure these emerging markers
of neuronal injury and synaptic dysfunction; visinin-like pro-
tein 1 (VILIP1), neurogranin (Ng), and synaptosomal-associated
alpha-synuclein (SNAP-25).87 We are using standard commer-
cial enzyme-linked immunosorbent assay (ELISA) to measure
chitinase-3-like protein (YKL-40) (a marker of astrogliosis/
neuroinflammation), NfL (a marker of axonal injury), and alpha-
synuclein (aSN). The team plans to assay all CSF-based mark-
ers in blood using electrochemiluminescence (ECL) and single
molecule array (SIMOA). Many of these assays in blood and CSF
will also be measured in post-mortem brain tissue (see the Neu-
ropathology Approaches section).
10 of 15 HANDEN ET AL.
2. Untargeted Approaches: Untargeted omics analyses provide exten-
sive, unbiased datasets that allow us and other investigators the
chance to explore emerging or as-yet-unknown hypotheses for AD
biomarkers in DS. We are not limiting the specific markers that are
being quantified, but acknowledge that the technologies employed
for each untargeted omic modality have limitations for the quality
of the data, the scope of coverage, or the certainty of analyte iden-
tity. Untargeted approaches that we are currently using include the
following:
a. GWAS: Untargeted genomic analysis is being conducted and
considers the entire genome beyond AD candidate genes that
have been previously identified in adults with DS, individuals
with ADAD, and in the general population.
b. Untargeted Proteomics Assays: Untargeted (shotgun) proteomics
are using dedicated MS equipment using standard protocols.
Proteins are being analyzed using the highly sensitive Orbitrap
Fusion Tribrid mass spectrometer in-line with a Dionex 3000
ultimate UHPLC using SPS-MS3-based tandem mass tag (TMT)
method. Data are annotated using Proteome Discoverer 2.2 for
database search and TMT reporter ions quantification.
c. Untargeted Metabolomics Assays: Untargeted metabolomics are
being performed using ultra-performance liquid chromatog-
raphy electro-spray ionization-quadrupole-time of flight-mass
spectrometry (UPLC-ESI-QTOF-MS) based data acquisition fol-
lowing standard protocols. Data are acquired in centroid MS
mode from 50 to 1200 m/z mass range for TOF-MS scanning
as single injection per sample. Approximately 1900 features are
identified by mass to charge ratio (m/z) in the positive ion mode
and ≈2800 features in the negative ion mode for a total of
≈4700 features. Putative features identified bym/z and column
retention time are expressed in relative abundance units.
10 NEUROPATHOLOGY APPROACHES
A neuropathological diagnosis is essential for a final diagnosis for
participants enrolled in ABC-DS and fulfills several important func-
tions including (1) providing reports to families, (2) providing a final
diagnosis to clinicians and researchers in ABC-DS, (3) obtaining
post-mortem neuroimaging outcomes to relate to ante-mortem imaging
and neuropathology, and (4) providing clinically characterized rapid
autopsy brain tissue for neurobiological studies dedicated to DS that
can be shared nationally and internationally. In ABC-DS, protocols for
the procurement of brain tissue and dissection use well established
methods used by Alzheimer’s Disease Centers.
This protocol involves the fixation of half of the brain in either 10%
formalin or 4% paraformaldehyde and obtaining frozen coronal sec-
tions of the left hemisphere. Prior to processing for a neuropatholog-
ical diagnosis, the ABC-DS study will now include post-mortem neu-
roimaging of the fixed hemisphere to obtain T1 MPRAGE, SWI and
T2 FLAIR sequences, if the participant had neuroimaging data prior to
death. Neuropathologic examination is performed blinded to clinical
information in accordance with current National Institute on Aging-
Alzheimer’s Association (NIA-AA) guidelines.88,89 Final NP and data
will be collected using theNational Alzheimer Coordinating Center NP
forms (NACC forms).90 When the neuropathology diagnosis is com-
pleted, neuropathology slides will be scanned (Aperio Versa system)
to acquire digital pathology images that can be shared and quanti-
fied using either or both positive pixel and the nuclear algorithms.91,92
Thus, neuropathology data that will be available include systematic
neuropathology data, digital images, quantitative measures of AD
pathology, post-mortem imaging, and rapid autopsy high quality tissue
for research.
11 BIOSTATISTICS AND DATA MANAGEMENT
Because the ABC-DS was originally developed as two separate pro-
grams, it was necessary to harmonize data across the program sites.
This task took≈8months and has been largely successful. Because the
two teams made significant investment in the original development of
their databases, each has continued to use separate systems during the
first few years of the project. However, variable definitions and values
were established for all harmonized procedures so that the data could
be compared across sites. The three ADDS sites have used the RED-
cap system for data entry and the four NiAD sites have entered web-
based data through the Alzheimer’s Therapeutic Research Institute
(ATRI). A transition is now underway in which all clinical, demographic,
and project management functionality will be transferred to the ATRI
system. Data (from the first assessment cycle) and research method-
ology is currently available to the scientific community through the
LONI.
The Biostatistics and Data Management Core has had two major
goals. The first was to develop a reliable and comprehensive database
that could make ABC-DS findings readily available to both con-
sortium investigators and to external researchers working in the
field. This has included clinical and neuropsychological data, neu-
roimaging scans, and biological samples. In addition, the results from
a range of analyses conducted by ABC-DS investigators (eg, pro-
teomics, metabolomics, and genetic analyses; MRI findings) will also
be shared with the greater research community. The second goal of
the Core has been to provide direct support to ABC-DS investiga-
tors in the development of additional research questions and data
analytics.
The biostatistical approach rests upon establishing a unified rela-
tional database across the key components of the project. As indicated
above, ADDS/NiAD harmonization has now largely been achieved. The
statistical approach involves an array of measures that can be com-
bined in multivariate models for biomarker characterization to predict
cognitive decline.
11.1 Longitudinal data modeling
As a study examining the relationship between a range of potential
biomarkers and functioning over time, longitudinal data modeling is an
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TABLE 7 Comparison of biomarkers obtained for various Alzheimer’s networks
Activity ADNI DIAN ABC-DS
Amyloid PET tracer Florbetapir (AV45) or florbetaben Pittsburgh compound B (PiB) Pittsburgh compound B (PiB)
or florbetapir (AV45)
Tau PET tracer [F-18]AV-1451
a
FDG PET tracer [F-18] FDG
MRI sequences T1-weightedMPRAGE, T2 FLAIR, T2 Star, DTI, pASL, Rs-fMRI
CSF analysis Univ. of Pennsylvania ADNI Biomarker Lab Washington Univ.
Fagan Biomarker Lab
Washington Univ.
Fagan Biomarker Lab
Biofluid storage NCRAD Washington Univ.
Fagan Biomarker Lab
NCRAD (plasma)
Washington Univ.
Fagan Biomarker Lab (CSF)
MRI QC Univ. ofMichigan
Koeppe Lab (NiAD) or internally (ADDS)
PETQC Mayo Clinic
Jack Lab (NiAD) or internally (ADDS)
Data base ATRI Washington Univ. ATRI
Data hosting LONI Washington Univ. LONI
ADDS, Alzheimer’s DiseaseDown Syndrome; ATR, Alzheimer Therapeutic Research Institute; CSF, cerebrospinal fluid; LONI, Laboratory ofNeuro Imaging at
USC; MRI, magnetic resonance imaging; NCRAD, The National Centralized Repository for Alzheimer’s Disease and Related Dementias; PET, positron emis-
sion tomography; QC, quality control; Univ., university.
aAlzheimer Disease Neuroimaging Initiative (ADNI) uses additional tau PET tracers as well.
important tool. By setting the outcome as one of the ATN biomark-
ers (A: amyloid, T: tau, N: neurodegeneration), linear mixed regres-
sion models93-95 have the feature to handle correlation in longitudinal
data and will allow us to estimate not only covariate effects, but also
biomarker changes/trajectories over time.
11.2 Survival analysis
Some of the standard techniques such as the Kaplan-Meier
estimator,96 log-rank tests,97 and Cox regression models,98 will
be employed to analyze survival data with right censoring when
the outcome variable is time to MCI-DS or DS-AD. For those study
participants with MCI-DS identified at baseline, only a proportion
have the medical record of initial diagnosis date. To avoid sampling
bias, the Cox model analysis will be extended and conducted based on
those MCI-free participants at baseline, where the failure time data
are known to be left-truncated and right-censored. Proper method
approaches will be adopted to handle the additional sampling bias due
to left truncation.99,100
11.3 ROC/AUC for biomarker evaluation
Conduct sensitivity and specificity analyses will be conducted for each
of the ATN biomarkers using the following parameters: (1) the receiver
operating characteristic (ROC) curve and area under the ROC curve
(AUC) for both binary outcome (MCI/no-MCI) defined at baseline
and time-to-disease outcome (such as age at diagnosis of MCI), and
(2) time from MCI to dementia using well-established methods and
software.101-104 All resulting statistical models will include adjustment
for site variability and procedures to ensure reproducibility of data as
well as rigor of approach.
12 ABC-DS PROTOCOL IN RELATION TO
ALZHEIMER’S DISEASE NEUROIMAGING INITIATIVE
(ADNI) AND DOMINANTLY INHERITED ALZHEIMER
NETWORK (DIAN)
The ABC-DS consortium is modeled, in part, after the ADNI and DIAN
projects. Over the past 15 to 20 years, NIA has devoted considerable
resources toward developing a wide range of common elements for
NIA-funded AD research. Consistent with the ADNI/DIAN projects,
the ABC-DS consortium has also included many of these elements
in data acquisition and management pipelines (see Table 7). How-
ever, some differences exist across ADNI, DIAN, and ABC-DS, espe-
cially in terms of the frequency of visits. The DIAN protocol has vis-
its at a 12-month interval for symptomatic participants and at a 24-
month interval for asymptomatic participants. ADNI evaluates par-
ticipants depending on their clinical status (cognitively normal [CN]
participants are seen every other year, MCI-DS participants are eval-
uated yearly, and AD participants are followed annually for a total
of three in-clinic visits and then followed by telephone interview).
ABC-DS visits are conducted every 16months, regardless of dementia
status.
The ADNI and DIAN protocols are developed around cores. The
ABC-DS team consists of cores focused on omics (genetic, CSF,
12 of 15 HANDEN ET AL.
proteomics, and metabolomics), neuroimaging (tau, amyloid, and FDG
PET; MRI), data, administrative, outreach, and clinical (neuropsycho-
logical assessment, caregiver questionnaires, medical and neurological
evaluations) and include assessments that are similar to ADNI/DIAN
protocols. Of necessity, the clinical measures represent the area of
greatest difference between the ABC-DS and ADNI/DIAN, as adults
with DS are unable to complete many of the standard AD neuropsy-
chological assessment tools (or would score within the MCI/AD range
on these tools). As detailed earlier, the same domains are assessed, but
with tools that limit floor effects for the DS population. Similarly, DS-
specific caregiver reporting tools are used to address similar domains
covered in the ADNI/DIAN protocols (eg, adaptive functioning, AD
symptoms, psychiatric symptoms). As a result, we anticipate that many
of theABC-DS findingswill be able tobe comparedand contrastedwith
the ADNI andDIAN populations. Finally, both the ADNI andDIAN net-
works have been in existence for considerably longer than the ABC-DS
(16 years and 12 years, respectively). Hence, both projects have been
able to follow their participants for more extended periods of time and
havebeenable todocumentearly changes leading toAD ina far greater
percentage of their cohorts.
We believe that results fromABC-DSwill inform our understanding
of the effects of known geneticmutations that lead toAD. Results from
both ABC-DS and DIANmay be models for the development of LOAD,
which is currently being evaluatedbyADNI. Furthermore, comparisons
between ABC-DS and DIAN will not only help elucidate the effects of
gene dosage on development of AD, but also will serve as cohorts to
assist in evaluating potential therapies for AD.
13 CHALLENGES
Because ABC-DS was created from the integration of two separate
programs, it was to be expected that some methodological differences
would be present. These included some differences in selected neu-
ropsychological assessment tools, different data coding systems, dif-
ferent acquisition sequences for MRI acquisition, and different ligands
for amyloid PET imaging. Many of the differences were based on the
rich trove of legacy data and experiences amassed by the many differ-
ent ABC-DS investigators, some of whom have been working in this
area for several decades. Thus, amajor challenge has been data harmo-
nization, exacerbated by the huge volume and diversity of data across
participating institutions and longitudinal time epochs. The ensuing
protocol harmonization effort has been quite successful but not per-
fect. Success can be claimed for harmonizing the medical evaluations,
most of the neuropsychological testing, omics determinations, and
many aspects of neuroimaging. As indicated above, differences remain
in some aspects of site-specific neuroimaging due to local ligand avail-
ability and some other factors. The creation of a Centiloid scale for DS
to harmonize data across different amyloid ligands is a bold step to
address this challenge.
There have also been challenges thatmay be inherent to conducting
researchwith adultswithDSand that are common to longitudinal stud-
ies in general. Recruitment of participants, especially of minorities, has
been a continuing challenge to most ABC-DS sites. This could impact
the representativeness of the study cohort to the overall population of
adults withDS. Participant burden (includingmultiple scans and exten-
sive neuropsychological assessment batteries) is always a concern and
can challenge staff ability to consistently collect all planned measures
and can adversely impact study retention. Many participants reside
in community residential programs, resulting in frequent changes in
staff across visits (with different “reporters” at each visit). The 5-year
study span naturally limits the number of participants transitioning in
status from CS to MCI-DS and to dementia within the limited dura-
tion of follow-up. Analysis issues arise, such as the proper handling of
missing data (both within study visits and due to participant drop-out).
There also remains a challenge in obtaining agreement for post-mortem
follow-up and in making such arrangements, should the opportunity
present itself. Finally, it is recognized that our consensus determina-
tions are inherently imperfect, especially in the accurate classification
of those individuals with possibleMCI-DS.
14 FUTURE PLANS
Future plans for ABC-DS are directed toward implementing a single
core protocol for all sites with follow-up visits continuing at 16-month
intervals. The number of enrolling sites is being expanded to add the
University of Kentucky and a new enrollment target of 550 individu-
als with DS has been set. A highly coordinated effort will be put into
place to enroll greater numbers of individuals from under-represented
minority groups (primarily Hispanic and African American). The major
programmatic aims will be to continue examination of the factors that
modify risk for AD in DS, to determine the genetic and biomarker
profile that modify risks within this high-risk population, to identify
biomarkers of AD progression that can inform diagnostic decisions in
clinical practice, and togenerate amulti-tieredapproach to indicate the
most favorable indications for successful clinical trial intervention.
Future integration of ABC-DS data with those of other national and
international initiatives, such as the Horizon 21 protocol in Europe,
hold even greater promise for biomarker discovery and for support-
ing clinical trials to prevent or treat AD in DS. To this end, the Consor-
tiumhasbegun collaboratingwith twoother programs: (1) theNACCto
develop a DSmodule that will include a harmonized subset of themea-
suresused in theABC-DSprotocol, and (2) theAlzheimer’sClinical Trial
Consortium forDown syndrome (ACTC-DS),which provides the infras-
tructure and support to bring researchers together to conduct clinical
trials for AD in DS across 15 international sites.
The ABC-DS is poised to have a substantial impact on our ability
to characterize AD in DS, both by identifying those biomarkers that
clarify risk for transition from cognitive stability to early clinical pro-
gression to AD and in the identification of biomarkers of preclinical
AD progression. Following the lead of outstanding established AD net-
works such as ADNI and DIAN, ABC-DS will also make a significant
contribution to national efforts to improve the quality of life of our
aging population through advancing progress toward effective preven-
tion and treatment of AD.We expect to provide exciting new leads into
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treatment targets for AD both for people with DS and, by translation,
to all people with or whowill develop AD.
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